Hoth Therapeutics Advances HT-001 Phase 2a Trial
NEW YORK, United States – May 5, 2026 Hoth Therapeutics, Inc. has announced that it secured regulatory authorization in...
Dermatology
Advertisement
LEO Pharma Acquires Replay to Boost Gene Therapy
Ballerup, Denmark | April 30, 2026 LEO Pharma has announced a definitive agreement to acquire Replay, significantly expanding its...
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
Vanda Pharma Publishes Phase III Imsidolimab Data
WASHINGTON, April 28, 2026 Vanda Pharmaceuticals Inc. has announced the publication of pivotal Phase III clinical data evaluating imsidolimab,...
Clinuvel Advances Vitiligo Phase 3 with EMA Support
MELBOURNE, Australia & AMSTERDAM, Netherlands, April 24, 2026 Clinuvel Pharmaceuticals Ltd has announced that it has received final Scientific...
Advertisements
LEO Pharma Wins China Approval for Enstilar Psoriasis Drug
BALLERUP, Denmark, April 17, 2026 LEO Pharma A/S has secured a major regulatory milestone with the approval of Enstilar®...
Triple Hair Group Advances TH07 Into Phase III Trial
SAN CARLOS, Calif., April 2, 2026 Triple Hair Group Inc. has announced that the first patient has been dosed...
Hoth HT-001 Meets Endpoint, Expands Phase 2 Trial in EU
NEW YORK, USA — April 1, 2026 Hoth Therapeutics, Inc. announced that its investigational therapy HT-001 has successfully met...
Beyond Facials Launches Needle-Free Collagen Skin Tech
SANTA MONICA, Calif., March 30, 2026 Beyond Facials, an advanced skincare innovation studio, has introduced its latest breakthrough treatment,...
Anumana Secures FDA Clearance for AI ECG Detection Tool
CAMBRIDGE, Mass., March 28, 2026 Anumana, an AI-driven cardiovascular health technology company, announced that the U.S. Food and Drug...
Advertisement
